Addex Therapeutics Ltd, a Swiss development-stage biopharmaceutical company, is pioneering the discovery, development, and commercialization of small-molecule pharmaceutical products aimed at treating various central nervous system (CNS) disorders. Specifically, the company is committed to identifying oral small molecule allosteric modulators of G-protein coupled receptors that can effectively treat CNS disorders. Its portfolio includes several lead programs, such as Dipraglurant - designed to alleviate Parkinson's disease levodopa-induced dyskinesia and dystonia - as well as ADX71149 - developed to address epilepsy and undisclosed CNS disorders - and GABAB PAM, which is focused on treating addiction. Addex Therapeutics has established numerous license and collaboration agreements, including deals with Janssen Pharmaceuticals Inc., Indivior PLC, and The CharcotMarieTooth Association. Formerly known as Addex Pharmaceuticals Ltd, the Geneva-based company underwent a name change to Addex Therapeutics Ltd in March 2012. Since its inception in 2002, Addex Therapeutics has been steadfast in its mission to enhance the treatment options for individuals living with CNS disorders.
Addex Pharmaceuticals's ticker is ADXN
The company's shares trade on the OTC stock exchange
They are based in Plan-les-Ouates, Switzerland
There are 11-50 employees working at Addex Pharmaceuticals
It is http://www.addexpharma.com/
Addex Pharmaceuticals is in the Healthcare sector
Addex Pharmaceuticals is in the Biotechnology industry
The following five companies are Addex Pharmaceuticals's industry peers: